According to the note, the Chinese Ministry of Defense has approved human clinical trials of a coronavirus vaccine developed by the Military Academy of Sciences, although the text did not specify when such trials would begin.
The vaccine was developed by the research team led by epidemiologist Chen Wei of the Military Academy of Medical Research, under the Military Academy of Sciences.
According to Chen, the vaccine – developed in line with “international standards and local regulations” – is prepared to carry out “large-scale, safe and effective production.”
On Tuesday (17.03.2020), several Chinese institutions announced that they will launch in April clinical trials to test the effectiveness of several vaccines the country is developing against the virus.
According to the Chinese Ministry of Education, there is a viral vector-based vaccine of influenza on the table that is currently undergoing animal experimentation that will begin clinical trials in April, with the participation of Beijing universities, Tsinghua and Xiamen, as well as other research institutions, according to the state news agency Xinhua.
In addition, the deputy director of the Shanghai Municipal Health Commission, Yi Chengdong, said that Chinese scientists have developed a vaccine on the mRNA platform that will enter clinical trials also in April. Yi noted that it has been developed based on viral proteins derived from the structural proteins of a virus.
Meanwhile, three new products used in diagnostic tests to detect coronavirus have been clinically approved and applied in Shanghai, Zhang Quan, director of the city’s science and technology commission, said today.
To date, at least 3,226 people have died from COVID-19 in China out of the 80,881 SARS-CoV-2 recorded since the epidemic began.
